Acadia Pharmaceuticals (ACAD) Assets Average (2011 - 2026)

Acadia Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 36.61% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 36.61% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 42.09% from the prior year.
• Assets Average improved to $1.6 billion in Q1 2026 per ACAD's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.6 billion in Q1 2026 and bottomed at $595.2 million in Q4 2022.
• The 5-year median for Assets Average is $802.0 million (2024), against an average of $908.6 million.
• Across the five-year window, Assets Average declined 16.4% in 2022 and soared 56.69% in 2024, its largest moves.
• Year by year, Assets Average stood at $595.2 million in 2022, then grew by 16.06% to $690.7 million in 2023, then surged by 56.69% to $1.1 billion in 2024, then surged by 33.74% to $1.4 billion in 2025, then rose by 9.48% to $1.6 billion in 2026.
• Per Business Quant, the three latest ACAD Assets Average figures stand at $1.6 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025).